Evidence map›Paper›PMID 37843384›Full record

ArticleJournal of the Pediatric Infectious Diseases Society2023

First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia.

Chishala Chabala, Tom G Jacobs, Cinta Moraleda, John M Ndaferankhande, Vivian Mumbiro, Alfeu Passanduca, Natasha Namuziya, Damalie Nalwanga, Victor Musiime, Alvaro Ballesteros and 18 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Pediatric Infectious Diseases Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 12 institutions in 9 countries.

Chishala ChabalaUniversity of Zambia, School of Medicine, Lusaka, Zambia.
Tom G JacobsDepartment of Pharmacy, Radboudumc Institute for Medical Innovation (RIMI), Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0001-5738-5528
Cinta MoraledaPediatric Unit for Research and Clinical Trials (UPIC), Hospital 12 de Octubre Health Research Institute (i+12), Biomedical Foundation of Hospital Universitario 12 de Octubre (FIB-H12O), Madrid, Spain.
John M NdaferankhandeMalawi-Liverpool-Wellcome Trust Clinical Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Vivian MumbiroUniversity of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.
Alfeu PassanducaUniversidade Eduardo Mondlane, Faculdade de Medicina, Maputo, Mozambique.
Natasha NamuziyaUniversity Teaching Hospital, Children's Hospital, Lusaka, Zambia.
Damalie NalwangaDepartment of Paediatrics and Child Health, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Victor MusiimeDepartment of Paediatrics and Child Health, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Alvaro BallesterosPediatric Unit for Research and Clinical Trials (UPIC), Hospital 12 de Octubre Health Research Institute (i+12), Biomedical Foundation of Hospital Universitario 12 de Octubre (FIB-H12O), Madrid, Spain.
Sara Domínguez-RodríguezPediatric Unit for Research and Clinical Trials (UPIC), Hospital 12 de Octubre Health Research Institute (i+12), Biomedical Foundation of Hospital Universitario 12 de Octubre (FIB-H12O), Madrid, Spain.ORCID 0000-0003-3747-9265
Moses ChitsamatangaUniversity of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.
Uneisse CassiaUniversidade Eduardo Mondlane, Faculdade de Medicina, Maputo, Mozambique.
Bwendo NdunaArthur Davidson Children's Hospital, Ndola, Zambia.
Justina BramugyCentro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
Jahit SacarlalUniversidade Eduardo Mondlane, Faculdade de Medicina, Maputo, Mozambique.
Lola MadridPediatric Unit for Research and Clinical Trials (UPIC), Hospital 12 de Octubre Health Research Institute (i+12), Biomedical Foundation of Hospital Universitario 12 de Octubre (FIB-H12O), Madrid, Spain.
Kusum J NathooUniversity of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.
Angela ColbersDepartment of Pharmacy, Radboudumc Institute for Medical Innovation (RIMI), Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-0389-9934
David M BurgerDepartment of Pharmacy, Radboudumc Institute for Medical Innovation (RIMI), Radboud University Medical Center, Nijmegen, The Netherlands.
Veronica MulengaUniversity of Zambia, School of Medicine, Lusaka, Zambia.
W Chris BuckUniversidade Eduardo Mondlane, Faculdade de Medicina, Maputo, Mozambique.
Hilda A MujuruUniversity of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.
Lindsey H M Te BrakeDepartment of Pharmacy, Radboudumc Institute for Medical Innovation (RIMI), Radboud University Medical Center, Nijmegen, The Netherlands.
Pablo RojoPediatric Unit for Research and Clinical Trials (UPIC), Hospital 12 de Octubre Health Research Institute (i+12), Biomedical Foundation of Hospital Universitario 12 de Octubre (FIB-H12O), Madrid, Spain.
Alfredo TagarroPediatric Unit for Research and Clinical Trials (UPIC), Hospital 12 de Octubre Health Research Institute (i+12), Biomedical Foundation of Hospital Universitario 12 de Octubre (FIB-H12O), Madrid, Spain.ORCID 0000-0003-2860-3455
Rob E AarnoutseDepartment of Pharmacy, Radboudumc Institute for Medical Innovation (RIMI), Radboud University Medical Center, Nijmegen, The Netherlands.
EMPIRICAL clinical trial group
University of Zimbabwe · ZWRadboud University Nijmegen · NLEduardo Mondlane University · MZUniversity Teaching Hospital · ZMUniversity of Liverpool · GBJoint Clinical Research Centre · UGLondon School of Hygiene & Tropical Medicine · GBMadrid Health Service · ESMakerere University · UGManhiça Health Research Centre · MZUniversidad Complutense de Madrid · ESUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optimal antituberculosis therapy is essential for favorable clinical outcomes. Peak plasma concentrations of first-line antituberculosis drugs in infants with living HIV receiving WHO-recommended dosing were low compared with reference values for adults, supporting studies on increased doses of first-line TB drugs in infants.

Indexed as

HIV InfectionsPneumoniaAdultAntitubercular AgentsHumansInfantReference ValuesAntitubercular AgentsHIVHRZEinfantspharmacokineticsTuberculosis

Identifiers

PMID37843384
PMCPMC10687595
OpenAlexW4387661818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.